Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

Phase 0 Completed 10 enrolled SWISS BIOPHARMA MED GmbH

NaSingle-groupOpen-labelTreatment

Summary

Phase 0/1 local application of the monoclonal antibody (Mab) sB24M in patients with purulent pyoderma (chronic ulcerative pyoderma) by injection into the affected areas. Monoclonal antibody (Mab) sB24 negatively regulates immune-inflammatory processes through CD47 / TNF-α Axis promotes epithelialization of damaged tissue.

Timeline

Start: 2021-05-24
Primary completion: 2023-03-10
Completion: 2023-03-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	sB24M	Monoclonal antibody	200 mg	Other

Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

Summary

Timeline

Drugs

Indications